Literature DB >> 26853750

HIF2α Is an Essential Molecular Brake for Postprandial Hepatic Glucagon Response Independent of Insulin Signaling.

Sadeesh K Ramakrishnan1, Huabing Zhang1, Shogo Takahashi2, Brook Centofanti1, Sarvesh Periyasamy1, Kevin Weisz1, Zheng Chen1, Michael D Uhler3, Liangyou Rui1, Frank J Gonzalez2, Yatrik M Shah4.   

Abstract

Glucagon drives hepatic gluconeogenesis and maintains blood glucose levels during fasting. The mechanism that attenuates glucagon action following refeeding is not understood. The present study demonstrates an increase in perivenous liver hypoxia immediately after feeding, which stabilizes hypoxia-inducible factor 2α (HIF2α) in liver. The transient postprandial increase in hepatic HIF2α attenuates glucagon signaling. Hepatocyte-specific disruption of HIF2α increases postprandial blood glucose and potentiates the glucagon response. Independent of insulin/AKT signaling, activation of hepatic HIF2α resulted in lower blood glucose, improved glucose tolerance, and decreased gluconeogenesis due to blunted hepatic glucagon action. Mechanistically, HIF2α abrogated glucagon-PKA signaling by activating cAMP-phosphodiesterases in a MEK/ERK-dependent manner. Repression of glucagon signaling by HIF2α ameliorated hyperglycemia in streptozotocin-induced diabetes and acute insulin-resistant animal models. This study reveals that HIF2α is essential for the acute postprandial regulation of hepatic glucagon signaling and suggests HIF2α as a potential therapeutic target in the treatment of diabetes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CREB; ERK; HIF2α; PKA; VHL; glucagon; hypoxia

Mesh:

Substances:

Year:  2016        PMID: 26853750      PMCID: PMC4785079          DOI: 10.1016/j.cmet.2016.01.004

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  45 in total

Review 1.  Regulation of hepatic blood flow: the hepatic arterial buffer response revisited.

Authors:  Christian Eipel; Kerstin Abshagen; Brigitte Vollmar
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

2.  Regulation of human metabolism by hypoxia-inducible factor.

Authors:  Federico Formenti; Dumitru Constantin-Teodosiu; Yaso Emmanuel; Jane Cheeseman; Keith L Dorrington; Lindsay M Edwards; Sandy M Humphreys; Terence R J Lappin; Mary F McMullin; Christopher J McNamara; Wendy Mills; John A Murphy; David F O'Connor; Melanie J Percy; Peter J Ratcliffe; Thomas G Smith; Marilyn Treacy; Keith N Frayn; Paul L Greenhaff; Fredrik Karpe; Kieran Clarke; Peter A Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

Review 3.  The role of dysregulated glucagon secretion in type 2 diabetes.

Authors:  D D'Alessio
Journal:  Diabetes Obes Metab       Date:  2011-10       Impact factor: 6.577

4.  ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish.

Authors:  Bin Ren; Yong Deng; Arpita Mukhopadhyay; Anthony A Lanahan; Zhen W Zhuang; Karen L Moodie; Mary Jo Mulligan-Kehoe; Tatiana V Byzova; Randall T Peterson; Michael Simons
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

5.  Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis.

Authors:  Aijuan Qu; Matthew Taylor; Xiang Xue; Tsutomu Matsubara; Daniel Metzger; Pierre Chambon; Frank J Gonzalez; Yatrik M Shah
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

Review 6.  The metabolic actions of glucagon revisited.

Authors:  Kirk M Habegger; Kristy M Heppner; Nori Geary; Timothy J Bartness; Richard DiMarchi; Matthias H Tschöp
Journal:  Nat Rev Endocrinol       Date:  2010-10-19       Impact factor: 43.330

7.  An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.

Authors:  Craig Cherrin; Kathleen Haskell; Bonnie Howell; Raymond Jones; Karen Leander; Ronald Robinson; Aubrey Watkins; Mark Bilodeau; Jacob Hoffman; Philip Sanderson; George Hartman; Elizabeth Mahan; Thomayant Prueksaritanont; Guoqiang Jiang; Qing-Bai She; Neal Rosen; Laura Sepp-Lorenzino; Deborah Defeo-Jones; Hans E Huber
Journal:  Cancer Biol Ther       Date:  2010-04-01       Impact factor: 4.742

Review 8.  Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?

Authors:  J N Walker; R Ramracheya; Q Zhang; P R V Johnson; M Braun; P Rorsman
Journal:  Diabetes Obes Metab       Date:  2011-10       Impact factor: 6.577

9.  STAT3 targets the regulatory regions of gluconeogenic genes in vivo.

Authors:  Preeti Ramadoss; Nathan E Unger-Smith; Francis S Lam; Anthony N Hollenberg
Journal:  Mol Endocrinol       Date:  2009-03-05

10.  Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice.

Authors:  Young Lee; May-Yun Wang; Xiu Quan Du; Maureen J Charron; Roger H Unger
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

View more
  20 in total

1.  Cellular circadian period length inversely correlates with HbA1c levels in individuals with type 2 diabetes.

Authors:  Flore Sinturel; Anne-Marie Makhlouf; Patrick Meyer; Christel Tran; Zoltan Pataky; Alain Golay; Guillaume Rey; Cédric Howald; Emmanouil T Dermitzakis; Claude Pichard; Jacques Philippe; Steven A Brown; Charna Dibner
Journal:  Diabetologia       Date:  2019-05-27       Impact factor: 10.122

2.  TGF-β1/Smad3 Pathway Targets PP2A-AMPK-FoxO1 Signaling to Regulate Hepatic Gluconeogenesis.

Authors:  Hariom Yadav; Samir Devalaraja; Stephanie T Chung; Sushil G Rane
Journal:  J Biol Chem       Date:  2017-01-09       Impact factor: 5.157

3.  Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis.

Authors:  Cen Xie; Tomoki Yagai; Yuhong Luo; Xianyi Liang; Tao Chen; Qiong Wang; Dongxue Sun; Jie Zhao; Sadeesh K Ramakrishnan; Lulu Sun; Chunmei Jiang; Xiang Xue; Yuan Tian; Kristopher W Krausz; Andrew D Patterson; Yatrik M Shah; Yue Wu; Changtao Jiang; Frank J Gonzalez
Journal:  Nat Med       Date:  2017-10-09       Impact factor: 53.440

4.  Long-range hypoxia signaling in NAFLD.

Authors:  Edward L LaGory; Amato J Giaccia
Journal:  Nat Med       Date:  2017-11-07       Impact factor: 53.440

5.  USP33 deubiquitinates and stabilizes HIF-2alpha to promote hypoxia response in glioma stem cells.

Authors:  Aili Zhang; Zhi Huang; Weiwei Tao; Kui Zhai; Qiulian Wu; Jeremy N Rich; Wenchao Zhou; Shideng Bao
Journal:  EMBO J       Date:  2022-02-22       Impact factor: 11.598

6.  HIF-2α Preserves Mitochondrial Activity and Glucose Sensing in Compensating β-Cells in Obesity.

Authors:  Jae-Su Moon; Matthew Riopel; Jong Bae Seo; Vicente Herrero-Aguayo; Roi Isaac; Yun Sok Lee
Journal:  Diabetes       Date:  2022-07-01       Impact factor: 9.337

Review 7.  The role of hypoxia-inducible factors in metabolic diseases.

Authors:  Frank J Gonzalez; Cen Xie; Changtao Jiang
Journal:  Nat Rev Endocrinol       Date:  2018-12       Impact factor: 43.330

8.  Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload.

Authors:  Andrew J Schwartz; Nupur K Das; Sadeesh K Ramakrishnan; Chesta Jain; Mladen T Jurkovic; Jun Wu; Elizabeta Nemeth; Samira Lakhal-Littleton; Justin A Colacino; Yatrik M Shah
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

Review 9.  Hypoxia-inducible factors and diabetes.

Authors:  Jenny E Gunton
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

Review 10.  The cyclic AMP signaling pathway: Exploring targets for successful drug discovery (Review).

Authors:  Kuo Yan; Li-Na Gao; Yuan-Lu Cui; Yi Zhang; Xin Zhou
Journal:  Mol Med Rep       Date:  2016-03-18       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.